Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 14, 2015
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study
Anthony Mills, Gordon Crofoot, Cheryl McDonald, et al.
AIDS (London, England)
|
July 16, 2019
Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen
Giuliano Rizzardini, Andrea Gori, Celia Miralles, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 2, 2016
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results
David Wohl, Shinichi Oka, Nathan Clumeck, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 20, 2018
The North-South Divide: Substance Use Risk, Care Engagement, and Viral Suppression Among Hospitalized Human Immunodeficiency Virus-Infected Patients in 11 US Cities
Morgan M Philbin, Daniel J Feaster, Lauren Gooden, et al.
Plos One
|
January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
Gregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Plos One
|
June 3, 2022
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
Michelle Cespedes, Moupali Das, J Carlo Hojilla, et al.
The Lancet. HIV
|
July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
Onyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 14, 2019
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul E Sax, Kristine M Erlandson, Jordan E Lake, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 14, 2021
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials
Kristine M Erlandson, Christoph C Carter, Kathleen Melbourne, et al.
American Journal of Public Health
|
April 21, 2012
Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial
Lisa R Metsch, Daniel J Feaster, Lauren Gooden, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 14, 2015
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study
Anthony Mills, Gordon Crofoot, Cheryl McDonald, et al.
AIDS (London, England)
|
July 16, 2019
Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen
Giuliano Rizzardini, Andrea Gori, Celia Miralles, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 2, 2016
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results
David Wohl, Shinichi Oka, Nathan Clumeck, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 20, 2018
The North-South Divide: Substance Use Risk, Care Engagement, and Viral Suppression Among Hospitalized Human Immunodeficiency Virus-Infected Patients in 11 US Cities
Morgan M Philbin, Daniel J Feaster, Lauren Gooden, et al.
Plos One
|
January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
Gregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Plos One
|
June 3, 2022
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
Michelle Cespedes, Moupali Das, J Carlo Hojilla, et al.
The Lancet. HIV
|
July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
Onyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 14, 2019
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul E Sax, Kristine M Erlandson, Jordan E Lake, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 14, 2021
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials
Kristine M Erlandson, Christoph C Carter, Kathleen Melbourne, et al.
American Journal of Public Health
|
April 21, 2012
Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial
Lisa R Metsch, Daniel J Feaster, Lauren Gooden, et al.
Page
of 7